Cochrane · systematic review · CD011604
Hydromorphone for neuropathic pain in adults
Stannard, C, Gaskell, H, Derry, S, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
Pain, Palliative and Supportive CareAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
2
No studies
4
Included studies
NR
No studies 4 · 66.7%Ungraded 0 · 0%Very low 2 · 33.3%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Oral hydromorphone compared with placebo for chronic neuropathic pain
Population: adults with chronic neuropathic pain
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Substantial benefit: ≥ 50% reduction in pain PGIC much improved Oral hydromorphone vs placebo | no estimate extracted | NR | No studies |
Moderate benefit: ≥ 30% reduction in pain PGIC much or very much improved Oral hydromorphone vs placebo | no estimate extracted | NR | No studies |
Lack of efficacy withdrawal in randomised double‐blind phase Oral hydromorphone vs placebo | no estimate extracted | 1 study · 94 participants | Very low |
Adverse event withdrawal in randomised double‐blind phase Oral hydromorphone vs placebo | no estimate extracted | 1 study · 94 participants | Very low |
Serious adverse events Oral hydromorphone vs placebo | no estimate extracted | NR | No studies |
Deaths Oral hydromorphone vs placebo | no estimate extracted | NR | No studies |